NeuroOne Medical Technologies Corporation Announces Successful Completion of Feasibility Study for Ablation Electrode

Company's combination recording and ablation technology is the next intended product in its technology pipeline

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed an animal feasibility study of its combination recording and ablation technology at T3 Labs and Georgia State/Georgia Tech Center for Advanced Brain Imaging in Atlanta Georgia under the guidance of Dr. Robert Gross of Emory University. The study evaluated the ability of the NeuroOne Evo® sEEG electrodes to record brain activity and then ablate brain tissue using radiofrequency thermocoagulation in a porcine model.

The Evo ablation electrode represents the Company’s first development effort for therapeutic technology and is expected to be the next product offering in its portfolio pending FDA clearance. The product is designed to provide the ability to both identify problematic areas of the brain causing seizures as well as ablate brain tissue to alleviate these symptoms. This would represent a major advancement in neurosurgery, given that patients must first undergo the diagnostic surgery and then schedule a future second surgery to ablate the problematic tissue.

Dr. Robert Gross of Emory says, “This pilot study will provide important data to inform the development of this technological solution that has the potential to improve treatment efficacy and patient comfort.”

“We are encouraged and excited by the results of this animal feasibility study. This technology offers the potential to perform two separate procedures using the same device during one hospital stay which we believe is a safer and more cost-effective approach for both the patient, health care provider and health care facility. Today, a patient often needs to have two separate hospitalizations for two separate surgeries typically with months between both procedures. Coupled with our recent partnership with RBC Medical to develop the radio frequency hardware, we are excited about the potential to offer a complete system for our customers” says Dave Rosa, CEO of NeuroOne.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  

By using this website you agree to accept Medical Device News Magazine Privacy Policy